Table 1. Patient Characteristics

| Variable               | n (%) |
|------------------------|-------|
| Median age (range)     | 54.2  |
| Sex                    |       |
| Female                 | 26 (53)|
| Male                   | 28 (47)|
| Race / Ethnicity       |       |
| White                  | 38 (69)|
| Black                  | 9 (17)|
| Hispanic               | 8 (16)|
| Mean BMI [range] kg/m² | 30.9  |
| Signs and Symptoms     |       |
| Abdominal pain         | 26 (67)|
| Subjective Fever       | 23 (41)|
| Documented Fever [≥104-4] | 7 (23)|
| Nausea / Fever         | 25 (50)|
| Diarrhea               | 9 (18)|
| Respiratory symptoms at time of cholecystitis | 20 (55)
| Location at symptom onset |       |
| ER admission           | 27 (60)|
| Treatment              | 3 (10)|
| Cholecystitis          | 22 (57)|
| Acalculus              | 11 (27)|
| Median Labs [range] at diagnosis |       |
| Alanine transaminase (ALT) IU/L | 32 [7 - 256]| |
| Aspartate aminotransferase (AST) IU/L | 25 [22 - 292]| |
| Alkaline phosphatase (ALP) IU/L | 78 [42 - 422]| |
| Total bilirubin mg/dL   | 0.7 [0.2 - 1.5]| |
| Maximum C-reactive protein (CRP) mg/dL | 18 [5.5 - 29]| |
| Treatment              |       |
| Antibiotics            | 22 (73)|
| Percutaneous drain      | 23 (57)|
| Surgery                | 27 (57)|
| Mean Time from Dx to Surgery | 26 days |
| Resolution of Symptoms at 30 Days |       |
| With surgery            | 8 (31)|
| Without surgery         | 32 (89)|
| 30-day Mortality        | 0 (0)|

Conclusion. Cholecystitis may be an uncommon complication of COVID-19 disease. Cholecystitis may manifest most often 2-4 weeks following SARS-CoV-2 infection. This timing is similar to that in Multisystem Inflammatory Syndrome following SARS-CoV-2 infection and given similarities in timing to we hypothesize that cholecystitis in our patients could be driven by immune activation.

Table 1. Antibiotic days of therapy in COVID-19 positive and COVID-19 negative patients.

| Month     | COVID-19-positive | COVID-19-negative | % difference |
|-----------|-------------------|-------------------|--------------|
| March-20  | 400.85            | 422.50            | -5.45%       |
| April-20  | 394.88            | 393.97            | -0.23%       |
| May-20    | 394.12            | 394.45            | -0.34%       |
| June-20   | 390.48            | 388.93            | -3.87%       |
| July-20   | 413.08            | 404.98            | 2.13%        |
| August-20 | 395.56            | 390.72            | -1.36%       |
| September-20 | 402.18    | 399.06            | -0.82%       |
| October-20| 406.50            | 401.80            | -1.13%       |
| November-20 | 404.41    | 393.56            | -2.77%       |
| December-20 | 431.70     | 389.41            | 11.68%       |
| Average DOT/1000 PD | 408.62            | 396.58            | 2.81%        |

Disclosures. Christopher Polk, MD, Atea (Research Grant or Support); Gillie (Advisor or Review Panel member, Research Grant or Support); Humanigen (Research Grant or SUPPORT); Regeneron (Research Grant or Support); Mindy Sampson, MD, Regeneron (Grant/Research Support); Catherine Passaretti, MD, Nothing to disclose.